此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

EncompaSSc:MTX-474 用于弥漫性皮肤系统性硬化症(dcSSc)受试者的评估

2026年10月1日 更新者:Mediar Therapeutics

一项2期随机、双盲、安慰剂对照研究,旨在评估MTX-474治疗弥漫性皮肤系统性硬化症(dcSSc)患者的安全性和有效性

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

研究概览

详细说明

Participants with dcSSc who meet the study's inclusion and exclusion criteria will be randomly assigned in a 3:2 ratio to receive MTX-474 or a matching placebo by intravenous (IV) infusion. Concomitant use of one of the approved dcSSc therapies (immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents) is permitted under certain criteria. Participants randomized to the MTX-474 arm of the study will receive an IV infusion every 4 weeks, beginning at Day 0 and ending at Week 20. The End of Treatment Visit will occur at Week 24, and a Safety Follow-Up Visit will occur at Week 28, 8 weeks after the final infusion. mRSS assessments will occur at Screening, Baseline, and at all subsequent treatment visits up to and including Week 24. Spirometry will be performed at screening and Weeks 12. HRCT will be performed at screening and week 24. DLCO will be performed at Screening. Skin biopsies will be performed at Baseline and Week 12. Participants will have blood drawn for safety assessment and to assess Ephrin receptor levels at Screening, Baseline and every 4 weeks until Week 28. Blood will be drawn for serum PK analyses relative to the first and last doses of MTX-474.

研究类型

介入性

注册 (估计的)

85

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Ancona、意大利、60126
        • 尚未招聘
        • EncompaSSc site in Ancona, Italy
        • 接触:
      • Catania、意大利、95123
        • 尚未招聘
        • EncompaSSc site in Catania, Italy
        • 接触:
      • Genoa、意大利、16132
        • 尚未招聘
        • EncompaSSc site in Genoa, Italy
        • 接触:
      • Milan、意大利、20122
        • 尚未招聘
        • EncompaSSc site in Milan, Italy
        • 接触:
      • Modena、意大利、41124
        • 尚未招聘
        • EncompaSSc site in Modena, Italy
        • 接触:
      • Roma、意大利、00128
        • 尚未招聘
        • EncompaSSc site in Roma, Italy
        • 接触:
      • Auckland、新西兰、2025
        • 招聘中
        • Aotearoa Clinical Trials
        • 首席研究员:
          • Mark Sapsford
        • 接触:
      • Hamilton、新西兰、3204
        • 招聘中
        • Waikato Hospital
        • 接触:
        • 首席研究员:
          • Kamal Solanki
      • La Tronche、法国、38700
        • 尚未招聘
        • EncompaSSc site in La Tronche, France
        • 接触:
      • Montpellier、法国、34090
        • 尚未招聘
        • EncompaSSc site in Montpellier, France
        • 接触:
      • Paris、法国、75014
        • 尚未招聘
        • EncompaSSc site in Paris, France
        • 接触:
      • Strasbourg、法国、67000
        • 尚未招聘
        • EncompaSSc site in Strasbourg, France
        • 接触:
      • Toulouse、法国、31059
        • 尚未招聘
        • EncompaSSc site in Toulouse, France
        • 接触:
      • Vandœuvre-lès-Nancy、法国、54500
        • 尚未招聘
        • EncompaSSc site in Vandœuvre-lès-Nancy, France
        • 接触:
      • Bydgoszcz、波兰、85-168
        • 尚未招聘
        • EncompaSSc site in Bydgoszcz, Poland
        • 接触:
      • Nowa Sól、波兰、67-100
        • 尚未招聘
        • EncompaSSc site in Nowa Sól, Poland
        • 接触:
      • Warsaw、波兰、00-874
        • 尚未招聘
        • EncompaSSc site in Warszawa, Poland
        • 接触:
      • Warsaw、波兰、02-507
        • 尚未招聘
        • EncompaSSc site in Warszawa, Poland
        • 接触:
    • Queensland
      • Southport、Queensland、澳大利亚、4222
        • 招聘中
        • Griffith University (Clinical Trial Unit)
        • 接触:
        • 首席研究员:
          • Gerald Tracey
      • Woolloongabba、Queensland、澳大利亚、4102
        • 招聘中
        • Veracity Clinical Research
        • 首席研究员:
          • Lynda Spelman
        • 接触:
    • Victoria
      • Heidelberg、Victoria、澳大利亚、3084
        • 招聘中
        • Austin Health
        • 首席研究员:
          • Jessica Leung
        • 接触:
      • Brasov、罗马尼亚、500283
        • 尚未招聘
        • EncompaSSc site in Brasov, Romania
        • 接触:
      • Bucharest、罗马尼亚、030463
        • 尚未招聘
        • EncompaSSc site in Bucharest, Romania
        • 接触:
      • Bucharest、罗马尼亚、041303
        • 尚未招聘
        • EncompaSSc site in Bucharest, Romania
        • 接触:
      • Timișoara、罗马尼亚、300133
        • 尚未招聘
        • EncompaSSc site in Timişoara, Romania
        • 接触:
    • Arizona
      • Phoenix、Arizona、美国、85054
        • 尚未招聘
        • EncompaSSc site in Phoenix, AZ
        • 接触:
    • California
      • La Jolla、California、美国、92037
        • 尚未招聘
        • EncompaSSc site in La Jolla, CA
        • 接触:
      • Loma Linda、California、美国、92350
        • 尚未招聘
        • EncompaSSc site in Loma Linda, CA
        • 接触:
      • Los Angeles、California、美国、90095
        • 招聘中
        • University of California Los Angeles Scleroderma Center
        • 首席研究员:
          • Elizabeth Volkmann
        • 接触:
      • Newport Beach、California、美国、92663
        • 招聘中
        • NewportNativeMD, Inc.
        • 首席研究员:
          • Ryan Klein
        • 接触:
      • Palo Alto、California、美国、94304
        • 尚未招聘
        • EncompaSSc site in Palo Alto, CA
        • 接触:
    • Colorado
      • Aurora、Colorado、美国、80045
        • 招聘中
        • University of Colorado Center for Lungs/Breathing/Scleroderma Clinic
        • 接触:
        • 首席研究员:
          • Melissa Griffith
    • Florida
      • Clearwater、Florida、美国、33765
        • 招聘中
        • Clinical Research of West Florida
        • 首席研究员:
          • Rodney Daniel
        • 接触:
      • Sarasota、Florida、美国、34239
        • 招聘中
        • Sarasota Arthritis Center
        • 首席研究员:
          • Jesse Boodoo
        • 接触:
      • Tampa、Florida、美国、33606
        • 招聘中
        • Clinical Research of West Florida
        • 首席研究员:
          • John Carter
        • 接触:
    • Kansas
      • Kansas City、Kansas、美国、66103
        • 尚未招聘
        • EncompaSSc site in Kansas City, KS
        • 接触:
    • Maryland
      • Baltimore、Maryland、美国、21205
        • 招聘中
        • Johns Hopkins University
        • 首席研究员:
          • Laura Hummers
        • 接触:
    • Massachusetts
      • Boston、Massachusetts、美国、02115
        • 招聘中
        • Brigham and Women's Hospital
        • 接触:
        • 首席研究员:
          • Avery LaChance
      • Boston、Massachusetts、美国、02118
        • 招聘中
        • Boston Medical Center
        • 接触:
        • 首席研究员:
          • Andreea Bujor
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • 尚未招聘
        • EncompaSSc site in Minneapolis, MN
        • 接触:
    • New York
      • Brooklyn、New York、美国、11201
        • 招聘中
        • NYU Langone Health
        • 首席研究员:
          • David Goddard
        • 接触:
    • Ohio
      • Cleveland、Ohio、美国、44195
        • 尚未招聘
        • EncompaSSc site in Cleveland, OH
        • 接触:
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • 招聘中
        • The University of Oklahoma Health Sciences Center
        • 接触:
        • 首席研究员:
          • Aikaterini Thanou
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • 尚未招聘
        • EncompaSSc site in Philadelphia, PA
        • 接触:
      • Pittsburgh、Pennsylvania、美国、15219
        • 招聘中
        • University of Pittsburgh Medical Center
        • 接触:
        • 首席研究员:
          • Christina Padilla
    • Texas
      • Allen、Texas、美国、75013
        • 招聘中
        • Stryde Research - DFW
        • 首席研究员:
          • John Lavery
        • 接触:
      • Dallas、Texas、美国、75246
        • 招聘中
        • Baylor Scott & White Research Institute
        • 接触:
        • 首席研究员:
          • Susan Mathai
      • Houston、Texas、美国、77030
        • 尚未招聘
        • EncompaSSc site in Houston, TX
        • 接触:
      • Coventry、英国、CV2 2DX
        • 尚未招聘
        • EncompaSSc site in Walsgrave Coventry, UK
        • 接触:
      • Liverpool、英国、L7 8XP
        • 招聘中
        • Royal Liverpool University Hospital
        • 首席研究员:
          • Marina Anderson
        • 接触:
      • London、英国、SW8 3RN
        • 尚未招聘
        • EncompaSSc site in London, UK
        • 接触:
      • Westcliff-on-Sea、英国、SS0 0RY
        • 尚未招聘
        • EncompaSSc site in Westcliff-on-Sea, UK
        • 接触:
      • Groningen、荷兰、9713 GZ
        • 尚未招聘
        • EncompaSSc site in Groningen, Netherlands
        • 接触:
      • Barcelona、西班牙、08003
        • 尚未招聘
        • EncompaSSc site in Barcelona, Spain
        • 接触:
      • Barcelona、西班牙、08025
        • 尚未招聘
        • EncompaSSc site in Barcelona, Spain
        • 接触:
      • Córdoba、西班牙、14004
        • 尚未招聘
        • EncompaSSc site in Córdoba, Spain
        • 接触:
      • Málaga、西班牙、29004
        • 尚未招聘
        • EncompaSSc site in Malaga, Spain
        • 接触:
      • Valencia、西班牙、46026
        • 尚未招聘
        • EncompaSSc site in Valencia, Spain
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Diagnosis of diffuse cutaneous systemic sclerosis, classified according to 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)

  2. Participant is either:

    1. Within 2 years of their first non-Raynaud's symptom and their mRSS is >7; OR
    2. >2 and ≤5 years from their first non-Raynaud's symptom, their mRSS is between 10 and 30, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS on exams performed by the same clinician, or (2) they were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done; OR
    3. >5 and ≤10 years from their first non-Raynaud's symptom, their mRSS is between >15 and ≤25, they are negative for the RNA polymerase 3 autoantibody, and (1) they have never had any previous spontaneous improvement in skin thickening of ≥4 points by mRSS, or (2) were never clinically noted to have a meaningful spontaneous reduction in skin thickness if mRSS was never done.
  3. Participant is ≥18 years of age at time of signing the ICF.

  4. Able to understand the study and provide a signed, written ICF

  5. Able to read and understand the language of the ICF and other study-related materials

  6. Forced vital capacity (FVCpp) of ≥45 pp10

  7. Have diffusing capacity of the lungs for carbon monoxide (DLCO) of ≥30 percent predicted at Screening

  8. Willing and able to complete all protocol-required study visits and procedures

  9. Participants of childbearing potential must have a negative serum pregnancy test at Screening.

  10. All participants with reproductive potential must agree to use and follow medically approved, highly effective methods of contraception during treatment and until 5 half-lives or 125 days after the last dose, whichever is longer

Exclusion Criteria:

  1. Concomitantly have another serious medical illness, which, in the opinion of the Investigator, would interfere with the participant's ability to complete the study

  2. Participant is currently on immunosuppressive therapy, systemic glucocorticoids or other antifibrotic agents detailed as follows:

    1. Immunosuppresive agents: Cyclophosphamide (IV or oral if used in the 6 months prior to Screening), calcineurin inhibitors (if used in the 30 days prior to Screening), azathioprine (if used in the 30 days prior to Screening), Janus-kinase inhibitors (if used in the 30 days prior to Screening), rituximab (if used in the 6 months prior to Screening), tocilizumab (if used in the 60 days prior to Screening) or any other biologic Disease-Modifying Antirheumatic Drugs (DMARD, if used in the last 30 days or 3 half-lives prior to Screening, whichever is longer)
    2. Antifibrotic agents: nintedanib or pirfenidone (if used in the 30 days prior to Screening). Also, exclusionary if used within 3 months of Screening are tyrosine-kinase inhibitors with recognized anti-fibrotic activity (imatinib, nilotinib, etc.)
    3. Systemic glucocorticoids: equivalent doses of prednisone greater than 10 mg/day (≤10 mg/day allowed). Has received any pulse intramuscular (IM) or intravenous (IV) steroid within 1 month of Screening
    4. Other agents:

    i. mycophenolate mofetil unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; ii. mycophenolic acid unless on a stable dose for at least 6 months prior to Screening and there are no plans to adjust the dose during the study; iii. hydroxychloroquine unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study; and iv. methotrexate unless on a stable dose for at least 3 months prior to Screening and there are no plans to adjust the dose during the study.

  3. Previous or planned hematopoietic stem cell or solid organ transplantation

  4. Previous treatment with chimeric antigen receptor (CAR)-T/CAR-NK therapy

  5. Clinically significant PAH as determined by the Investigator at, or prior to first day of dosing (Baseline)

  6. Current use of PAH medication (endothelin receptor antagonists, prostacyclin analogues, soluble guanylate cyclase stimulators) excluding calcium channel blockers and phosphodiesterase-5 inhibitors

  7. Pregnant or currently breastfeeding

  8. Aspartate transaminase (AST) or alanine transaminase (ALT) >2.0 upper limit of normal

  9. Creatinine clearance <45mL/min

  10. History of myocardial infarction, angina or congestive heart failure

  11. International normalized ratio >2 or partial thromboplastin time >1.5 × upper limit of normal

  12. Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

  13. History of clinically significant thrombotic event within 12 months prior to Screening

  14. Positive anticentromere antibody

  15. Systemic sclerosis renal crisis within 12 months prior to Screening

  16. Confirmed diagnosis of overlap syndrome, systemic lupus erythematosus with anti-double strand (ds)DNA antibody, rheumatoid arthritis with anti-cyclic citrullinated peptide (anti-CCP) antibody, or systemic sclerosis mimics (eosinophilic fasciitis, scleromyxedema) at the time of inclusion in the study

  17. Known malignancy or history of malignancy within 5 years of Screening other than non-melanoma skin cancer and in situ cervical cancer

  18. Major surgery within 8 weeks prior to Screening or planned surgery during study period

  19. Unable to routinely access veins for blood draws and IV infusions

  20. Currently receiving another experimental agent or participating in another clinical trial. If a participant has recently received another experimental agent, then the last dose must have been at least 5 half-lives or 30 days (whichever is longer) prior to Screening

  21. History of myocardial infarction, angina or congestive heart failure

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Placebo

Placebo

实验性的:MTX-474

MTX-474

Dosage level: 4 mg/kg Unit dose strength: 50mg/ml MTX-474 is a human immunoglobulin G1 (IgG1) monoclonal antibody that binds the human EphrinB2 with high specificity and high affinity. MTX-474 is being developed as a therapy for patients with systemic sclerosis (SSc).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in Modified Rodnan Skin Score (mRSS)
大体时间:Baseline to week 24

Mean change from baseline to week 24 in the modified Rodnan Skin Score, a clinician-assessed measure of skin thickness across 17 body areas.

Unit of measure: Score (range 0-51)

Baseline to week 24

次要结果测量

结果测量
措施说明
大体时间
Proportion of participants with a gene signature response in skin biopsy
大体时间:12 weeks

Proportion of participants in each arm (MTX-474 and placebo) demonstrating a dcSSc gene expression signature response on skin biopsy at Week 12.

Unit of Measure: Participants (%)

12 weeks
Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests
大体时间:Baseline through end of study (week 28)

Number of participants with clinically significant findings on physical examination, vital signs, and clinical laboratory tests Unit of Measure: Participants (%)

Baseline through end of study (week 28)
Number of participants with dose interruptions or treatment discontinuations due to adverse events
大体时间:Baseline through end of study (week 28)

Number of participants with dose interruptions or treatment discontinuations due to adverse events Unit of Measure: Participants (%)

Baseline through end of study (week 28)
Safety and tolerability of MTX-474 in participants with dcSSc: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs)
大体时间:Baseline through end of study (week 28)

Incidence, seriousness, and severity of TEAEs and TRAEs as determined by investigator assessment.

Unit of measure: Participants (%)

Baseline through end of study (week 28)
Serum concentration of MTX-474 at sparse PK time points
大体时间:Baseline to week 28

Serum MTX-474 concentrations collected at predefined sparse PK time points to support population pharmacokinetic (popPK) analysis Unit of Measure: ng/mL

Baseline to week 28
Clearance (CL) of MTX-474
大体时间:Baseline to week 28

Clearance of MTX-474 calculated from serial PK sampling using noncompartmental analysis Unit of Measure: L/hour

Baseline to week 28
Terminal elimination half-life (t½) of MTX-474
大体时间:Baseline to week 28

Terminal elimination half-life of MTX-474 derived from serial PK sampling. Unit of Measure: Hours

Baseline to week 28
Area under the plasma concentration-time curve (AUC) of MTX-474
大体时间:Baseline to week 28

AUC of MTX-474 calculated from serial PK sampling using noncompartmental analysis.

Unit of Measure: ng·h/mL

Baseline to week 28

其他结果措施

结果测量
措施说明
大体时间
Proportion of participants with a response on the revised American College of Rheumatology Composite Response Index in Systemic Sclerosis (rACR-CRISS)
大体时间:Baseline to week 24

Proportion of participants achieving rACR-CRISS composite response Unit of Measure: Participants (%)

Baseline to week 24
Change from baseline in Physician Global Assessment (PhGA) of disease status
大体时间:Baseline to week 24

Mean change from baseline to week 24 in the physician global assessment (phGA) of disease status in each arm Unit of Measure: Units on 0-10 visual analog scale (higher score = worse disease)

Baseline to week 24
Change from baseline in Patient Global Assessment (PtGA) of disease status
大体时间:Baseline to week 24

Mean change from baseline to week 24 in the patient global assessment (PtGA) of disease status in each arm Unit of Measure: Units on 0-10 visual analog scale (higher score = worse disease)

Baseline to week 24
Change from baseline in percent predicted forced vital capacity (FVCpp)
大体时间:Baseline to week 24

Mean change from baseline to week 24 on percent predicted forced vital capacity (FVCpp) Unit of Measure: Percent predicted (%)

Baseline to week 24
Change from baseline in quantitative interstitial lung disease (QILD) score by high-resolution computed tomography (HRCT)
大体时间:Baseline to week 24

Mean change from baseline to week 24 in the QILD score by high resolution computed tomography scan (HRCT) in each arm Unit of Measure: Units on QILD score (0-100 scale; higher score = greater fibrosis)

Baseline to week 24
Change from Baseline in free EphrinB2 levels
大体时间:Baseline to week 24

Median change from baseline to Week 24 in serum free EphrinB2 levels in each treatment arm.

Unit of Measure: pg/mL

Baseline to week 24
Change from baseline in forced vital capacity (FVC) by EphrinB2 levels
大体时间:Baseline to week 24

Mean change from baseline to Week 24 in FVC, analyzed by baseline EphrinB2 levels, in the subset of participants with interstitial lung disease (ILD).

Unit of Measure: Percent predicted (%)

Baseline to week 24
Proportion of participants achieving rACR-CRISS response by EphrinB2 levels
大体时间:Up to 24 weeks

Proportion of participants achieving a response on the revised ACR Composite Response Index in Systemic Sclerosis (rACR-CRISS), stratified by baseline EphrinB2 levels.

Unit of Measure: Participants (%)

Up to 24 weeks
To assess the presence, titer and impact of antidrug antibodies (ADA) against MTX-474
大体时间:Baseline to week 28

Samples will be collected from baseline until Week 28 to assess the rate at which antibodies develop to the study drug Unit of Measure: Titer units

Baseline to week 28
Change from baseline in expression of total and phosphorylated EphB2, EphB3, and EphB4 receptors in skin
大体时间:Baseline to Week 12

Mean change from baseline to Week 12 in total and phosphorylated EphB2, EphB3, and EphB4 receptor expression in skin biopsy samples.

Unit of Measure: Relative expression units (fold change from baseline)

Baseline to Week 12
Change from baseline in transcriptomic profile
大体时间:Baseline to Week 12

Change from baseline to Week 12 in global transcriptomic profile via bulk RNA sequencing analysis of skin biopsies in each arm.

Unit of Measure: Differential gene expression (log₂ fold change)

Baseline to Week 12
Change from baseline in serum biomarkers of organ involvement
大体时间:Baseline to weeks 12 and 24

Change from baseline to Weeks 12 and 24 in serum levels biomarkers, including but not limited to, ProC3 and IL-6 associated with organ involvement Unit of Measure: ng/mL (or unit per biomarker)

Baseline to weeks 12 and 24
Change from baseline in fatigue symptoms (FACIT-Fatigue score)
大体时间:Baseline to week 24

Mean change from baseline to Week 24 in fatigue symptoms as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue Scale.

Unit of Measure: Units on FACIT-Fatigue scale (range 0-52; higher score = less fatigue)

Baseline to week 24
Change from baseline in gastrointestinal (GI) symptoms (UCLA SCTC GIT 2.0 score)
大体时间:Baseline to week 24

Mean change from baseline to Week 24 in GI symptom burden assessed by the UCLA SCTC GIT 2.0 questionnaire.

Unit of Measure: Units on UCLA SCTC GIT 2.0 total score (range 0-3; higher score = worse symptoms)

Baseline to week 24
Change from baseline in anxiety and depression symptoms (HADS)
大体时间:Baseline to week 24

Mean change from baseline to Week 24 in symptoms of anxiety and depression measured by the HADS instrument.

Unit of Measure: Units on Hospital Anxiety and Depression Scale (HADS total and subscale scores; range 0-21 per subscale; higher score = worse symptoms)

Baseline to week 24
Change from baseline in HAQ-DI
大体时间:Baseline to week 24

Mean change from Baseline in functional disability as assessed by HAQ-DI. Unit of measure: Score (0-3 scale)

Baseline to week 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月16日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2025年11月18日

首先提交符合 QC 标准的

2025年12月12日

首次发布 (实际的)

2025年12月17日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • MTX-474-S201
  • 2025-523288-39 (EudraCT编号)
  • 2025 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅